Literature DB >> 6370414

Pulmonary blastoma. Case report and literature review of chemotherapy experience.

C A Medbery, M C Bibro, J C Phares, S R Veach, J E Martin, D N Pasquale.   

Abstract

Pulmonary blastoma is a rare primary lung neoplasm, occurring in both children and adults, which is pathologically, clinically, and prognostically distinct from other lung tumors. Usually it has been treated with surgery, but both chemotherapy and radiotherapy have been used for metastatic disease, and in the adjuvant setting. A patient is described who presented with metastatic pulmonary blastoma. Treatment with cyclophosphamide, vincristine, doxorubicin, and dactinomycin resulted in an objective response as judged by standard criteria. The literature is reviewed for other experience with chemotherapy in this rare lung tumor. This four-drug combination appears to show promise for tumor response, and is deserving of further trial.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6370414     DOI: 10.1002/1097-0142(19840601)53:11<2413::aid-cncr2820531108>3.0.co;2-e

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Pulmonary blastoma: report of a case.

Authors:  N Ohara; O Tominaga; T Oka; R Motoi; H Nakano; T Muto
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

2.  The Radiologic and Pathologic Diagnosis of Biphasic Pulmonary Blastoma.

Authors:  Fadi Nemeh; Anderson H Kuo; Jenny Ross; Carlos S Restrepo
Journal:  J Radiol Case Rep       Date:  2017-09-30

Review 3.  Pulmonary blastoma--a rare tumour.

Authors:  V Kliem; M Bügge; K Leimenstoll; H Maschek
Journal:  Clin Investig       Date:  1992-10

4.  What do we know about pulmonary blastoma?: review of literature and clinical case report.

Authors:  Dorota Brodowska-Kania; Ewa Kotwica; Aleksandra Paturej; Witold Sośnicki; Janusz Patera; Agnieszka Giżewska; Stanisław Niemczyk
Journal:  Nagoya J Med Sci       Date:  2016-12       Impact factor: 1.131

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.